1Multiple sclerosis (MS) is a chronic autoimmune condition in which the body’s immune system mistakenly attacks the myelin sheath, the fatty covering that insulates nerve fibres in the central nervous system. When myelin is damaged, electrical impulses between the brain and the rest of the body slow down or become blocked, causing symptoms such as muscle weakness, fatigue, visual disturbances, pain, and coordination difficulties. More than twenty therapies currently exist for relapsing forms of MS, but nearly all are designed to suppress immune activity. While this reduces the number of relapses, it does not reverse or repair damage that has already occurred. As a result, many patients continue to experience gradual neurological decline, leading to a strong need for therapies that can directly promote nerve repair.
2A new study led by researchers at the University of Cambridge has drawn attention for its potential to address this gap. The trial investigated a combination of two established medicines—metformin, widely used in the treatment of type 2 diabetes, and clemastine, a decades-old antihistamine. Both drugs are inexpensive, well known, and widely available. The key question was whether they could work together to stimulate remyelination, the biological process by which new myelin is generated to replace what has been lost. Preliminary results, presented at an international MS research conference, suggest the combination may stabilise nerve conduction in affected patients. If verified in larger trials, this approach could represent a new therapeutic pathway aimed not only at suppressing immune activity but also at actively repairing damaged nerve tissue.
3The scientific rationale emerged from earlier laboratory experiments in rodents and cell cultures. Clemastine alone had previously been shown to modestly promote the differentiation of precursor cells into oligodendrocytes, the specialised cells responsible for producing myelin. However, its effect was limited and inconsistent. Metformin, on the other hand, appears to restore ageing stem cells to a more youthful state, making them more capable of generating oligodendrocytes. When the two drugs were combined, researchers observed a synergistic effect: myelin regenerated more efficiently, and signal conduction along damaged axons improved. These preclinical findings created strong justification for testing the approach in a human population, leading to the trial known as CCMR-Two.
4The CCMR-Two trial enrolled around seventy participants diagnosed with relapsing MS. Volunteers were randomly assigned either the drug combination or a placebo and were followed for six months. The main outcome measure was the latency of visual evoked potentials, which record the time taken for electrical signals to travel from the eye to the brain in response to visual stimuli. This measure provides a sensitive marker of conduction speed in demyelinated pathways. Patients receiving the drug combination demonstrated stable or improved conduction times, while those on placebo experienced the expected decline over the study period. Although the trial was relatively small, these findings indicate that the drug pairing can at least prevent further deterioration of nerve conduction, a meaningful biological signal.
5It is important to note, however, that patients did not report substantial improvements in daily symptoms during the six-month period. MS-related difficulties such as mobility restrictions, fatigue, and cognitive slowing are unlikely to improve in such a short timeframe. The purpose of remyelination is not to create immediate symptom relief but to protect axons from long-term degeneration. If nerves can be stabilised, it may prevent disability from worsening over a period of years or decades. This distinction is crucial: biological markers can improve well before patients perceive tangible benefits. Longer and larger studies will be required to confirm whether stabilising conduction leads to better functional outcomes.
6Safety and tolerability are also critical considerations. Both metformin and clemastine are considered safe in their conventional uses, but their combined effect in people with MS has not been thoroughly characterised. Potential interactions with disease-modifying therapies, risks of long-term use, and variability in patient tolerance are areas requiring close study. Clinicians emphasise that patients should not attempt to access or combine these drugs outside clinical trials, since optimal dosing and treatment duration are not yet established. Researchers are cautious but optimistic, stressing the importance of continued investigation before any changes are made to clinical guidelines.
7Nevertheless, the trial has generated significant excitement in the MS community. For decades, research and treatment have focused primarily on immune suppression. The possibility of restoring myelin represents a shift in therapeutic philosophy, offering the potential not only to slow disease progression but also to repair prior damage. If larger-scale studies confirm the protective effect of the metformin–clemastine combination, it could usher in a new class of regenerative treatments. For the estimated 150,000 people living with MS in the United Kingdom, and millions worldwide, this approach could eventually help preserve independence, protect cognitive and physical function, and significantly improve long-term quality of life.